Profile - To The Moon

JORDBULL

Posts · 3Posts · 3
Following · 0Following · 0
Followers · 0Followers · 0

- JORDBULLJORDBULL
  ·2021-04-15
  Hmm
  3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?
  These stocks are red-hot so far this year. But could they cool off in the coming months?
  3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?
  62 Comment
  1
  Share
  Report
- JORDBULLJORDBULL
  ·2021-04-14
  Why?
  The Bear Thesis Against Palantir Is Rooted in Illogical Conclusions
  Follow the PLTR stock bull thesis and get in cheap.There’s a lot of negative sentiment surroundingPa
  The Bear Thesis Against Palantir Is Rooted in Illogical Conclusions
  102 Comment
  1
  Share
  Report
- JORDBULLJORDBULL
  ·2021-04-14
  ?
  Play Tilray Stock for the Aphria Stock Merger Arbitrage Opportunity
  This short-term opportunity will become a buy-and-hold investment once the merger closes. Aphria(NA
  Play Tilray Stock for the Aphria Stock Merger Arbitrage Opportunity
  66 Comment
  Like
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3567123115497130","uuid":"3567123115497130","gmtCreate":1604030025529,"gmtModify":1607351229993,"name":"JORDBULL","pinyin":"jordbull","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/4b95853b965a467335a4ba3aa97aa3df","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":18,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.64%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":347885685,"gmtCreate":1618484853147,"gmtModify":1704711543224,"author":{"id":"3567123115497130","authorId":"3567123115497130","name":"JORDBULL","avatar":"https://static.tigerbbs.com/4b95853b965a467335a4ba3aa97aa3df","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567123115497130","idStr":"3567123115497130"},"themes":[],"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/347885685","repostId":"2127001675","repostType":4,"repost":{"id":"2127001675","pubTimestamp":1618483800,"share":"https://ttm.financial/m/news/2127001675?lang=&edition=fundamental","pubTime":"2021-04-15 18:50","market":"us","language":"en","title":"3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127001675","media":"Motley Fool","summary":"These stocks are red-hot so far this year. But could they cool off in the coming months?","content":"<blockquote><b>These stocks are red-hot so far this year. But could they cool off in the coming months?</b></blockquote><p>Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.</p><p>You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.</p><p><img src=\"https://static.tigerbbs.com/d8fcf5763d8ca2f10309e3f278c4e0b7\" tg-width=\"700\" tg-height=\"473\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Aphria</h3><p><b>Aphria</b> (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind only<b>Sundial Growers</b>. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.</p><p>The biggest factor driving investors' interest in Aphria is the company's plans to merge with<b>Tilray</b> (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.</p><p>Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto its<b>Nasdaq</b>&nbsp;listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.</p><h3><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></h3><p>There's a genomics revolution underway right now. Surprisingly, though, only <a href=\"https://laohu8.com/S/AONE\">one</a> pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b> (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p><p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p><p>Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p><h3>Ocugen</h3><p><b>Ocugen</b> (NASDAQ:OCGN) stands out as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.</p><p>Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.</p><p>Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.</p><p><b>Are they buys now?</b></p><p>There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.</p><p>For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.</p><p>Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.</p><p>What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.</p><p>Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"APHA":"Aphria Inc.","BNGO":"Bionano Genomics","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127001675","content_text":"These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.Image source: Getty Images.AphriaAphria (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind onlySundial Growers. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.The biggest factor driving investors' interest in Aphria is the company's plans to merge withTilray (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto itsNasdaq listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.Bionano GenomicsThere's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger isBionano Genomics (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.OcugenOcugen (NASDAQ:OCGN) stands out as one of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.Are they buys now?There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":62,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":344509501,"gmtCreate":1618412889703,"gmtModify":1704710518064,"author":{"id":"3567123115497130","authorId":"3567123115497130","name":"JORDBULL","avatar":"https://static.tigerbbs.com/4b95853b965a467335a4ba3aa97aa3df","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567123115497130","idStr":"3567123115497130"},"themes":[],"htmlText":"Why?","listText":"Why?","text":"Why?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344509501","repostId":"1193747033","repostType":4,"repost":{"id":"1193747033","pubTimestamp":1618404624,"share":"https://ttm.financial/m/news/1193747033?lang=&edition=fundamental","pubTime":"2021-04-14 20:50","market":"us","language":"en","title":"The Bear Thesis Against Palantir Is Rooted in Illogical Conclusions","url":"https://stock-news.laohu8.com/highlight/detail?id=1193747033","media":"InvestorPlace","summary":"Follow the PLTR stock bull thesis and get in cheap.There’s a lot of negative sentiment surroundingPa","content":"<blockquote>Follow the PLTR stock bull thesis and get in cheap.</blockquote><p>There’s a lot of negative sentiment surrounding<b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) stock. A good number of headlines will imply that the company hasn’t done well, or is suddenly at risk of implosion.</p><p>Yet, when you dig into the numbers and strategy, Palantir looks like a strong company underpinned by growth. The argument against Palantir usually centers around its controversial nature and the concentration of its business. Palantir’s controversial nature is largely subjective of course.</p><p>What I see when I dig into Palantir is a company that is improving and somewhat misunderstood. That’s why the bullish case for buying in at today’s low prices makes sense.</p><p><b>Longer Term</b></p><p>It’s easy to look at a given company’s stock and judge it by a slide in price or short-term negative news. Yet, when establishing a long-term, buy-and-hold position, it makes sense to consider a company’s performance on a year over year basis.</p><p>And that’s a good place to start to understand why PLTR stock is now an opportune purchase. The company only recently had its IPO in late September, so let’s look at some recent years’ broad metrics for Palantir.</p><p>Revenues, profits and margins are all improving at Palantir over the past few years. Investors shouldn’t get overly concerned that Palantir isn’t the largest defense contractor, or that Palantir has a business concentrated in that specific sector.</p><p>So, back to those revenue, profit, and margin metrics. Palantir’s 2020 revenues hit $1.1 billion, up 47% from 2019 when it recorded $742.6 million in revenues. The company’s gross profit in 2020 was $740.1 million, up from $500.2 million in 2019. That means the gross margin grew from 67% to 68% between 2019 and 2020.</p><p>Honestly, this broad growth is more indicative of a company that makes sense investment-wise. I’d argue that much of the negative sentiment against Palantir is from pundits who simply can’t or won’t see the forest for the trees.</p><p>So, let’s look at the trees clouding their vision.</p><p><b>Naysayers</b></p><p>Anargument I read from priorto Palantir’s IPO stated:</p><blockquote>For investors, the most concerning might be its high customer concentration. Palantir said its top 20 customers accounted for 67% of its 2019 revenue, while its top three customers made up 28%. In fact, a single commercial customer accounted for 12% of its 2019 revenue. Losing any one of those major customers could have a big financial impact on Palantir’s business.</blockquote><p>The argument relies on the idea that Palantir is incapable of maintaining the business relationship that it has forged in the private and public sectors.</p><p>But that doesn’t hold up based on Palantir’syear-end 2020 report.</p><p>Government customer revenue increased by 77% between 2019 and 2020 at Palantir. $234.3 million of that $264.7 million increase was attributable to existing customers. Therefore, 88% of the government revenue increase came from existing contracts. This is a company that is providing services that its clients respect and will pay more for over time, not one in danger of losing customers.</p><p>On the commercial side Palantir saw its revenues grow 22% in the same time frame. $59.7 million (69.9%) of the $85.4 million in revenue growth was from existing clients. Again, satisfied customers is the narrative I see here.</p><p>If Palantir is doing something wrong by expanding their business within the contracts they currently have, then what should they do? Would markets be more impressed if the company were to land clients only not to see their respective businesses grow on an account-by-account basis?</p><p>Show me that Palantir’s business isn’t growing based on revenues, profits or some other meaningful basis and I’d be inclined to be bearish long term. That isn’t the case.</p><p><b>Verdict</b></p><p>Bears are essentially arguing that Palantir keeps ingratiating themselves to those that they provide services for. However, Palantir simply continues to grow those businesses, and that’s somehow a bad thing?</p><p>Seems an odd argument to me.I think PLTR stock prices now are an excellent spot from which to establish a position.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Thesis Against Palantir Is Rooted in Illogical Conclusions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Thesis Against Palantir Is Rooted in Illogical Conclusions\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/04/the-bear-thesis-against-pltr-stock-is-rooted-in-illogical-conclusions/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Follow the PLTR stock bull thesis and get in cheap.There’s a lot of negative sentiment surroundingPalantir(NYSE:PLTR) stock. A good number of headlines will imply that the company hasn’t done well, or...</p>\n\n<a href=\"https://investorplace.com/2021/04/the-bear-thesis-against-pltr-stock-is-rooted-in-illogical-conclusions/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2021/04/the-bear-thesis-against-pltr-stock-is-rooted-in-illogical-conclusions/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193747033","content_text":"Follow the PLTR stock bull thesis and get in cheap.There’s a lot of negative sentiment surroundingPalantir(NYSE:PLTR) stock. A good number of headlines will imply that the company hasn’t done well, or is suddenly at risk of implosion.Yet, when you dig into the numbers and strategy, Palantir looks like a strong company underpinned by growth. The argument against Palantir usually centers around its controversial nature and the concentration of its business. Palantir’s controversial nature is largely subjective of course.What I see when I dig into Palantir is a company that is improving and somewhat misunderstood. That’s why the bullish case for buying in at today’s low prices makes sense.Longer TermIt’s easy to look at a given company’s stock and judge it by a slide in price or short-term negative news. Yet, when establishing a long-term, buy-and-hold position, it makes sense to consider a company’s performance on a year over year basis.And that’s a good place to start to understand why PLTR stock is now an opportune purchase. The company only recently had its IPO in late September, so let’s look at some recent years’ broad metrics for Palantir.Revenues, profits and margins are all improving at Palantir over the past few years. Investors shouldn’t get overly concerned that Palantir isn’t the largest defense contractor, or that Palantir has a business concentrated in that specific sector.So, back to those revenue, profit, and margin metrics. Palantir’s 2020 revenues hit $1.1 billion, up 47% from 2019 when it recorded $742.6 million in revenues. The company’s gross profit in 2020 was $740.1 million, up from $500.2 million in 2019. That means the gross margin grew from 67% to 68% between 2019 and 2020.Honestly, this broad growth is more indicative of a company that makes sense investment-wise. I’d argue that much of the negative sentiment against Palantir is from pundits who simply can’t or won’t see the forest for the trees.So, let’s look at the trees clouding their vision.NaysayersAnargument I read from priorto Palantir’s IPO stated:For investors, the most concerning might be its high customer concentration. Palantir said its top 20 customers accounted for 67% of its 2019 revenue, while its top three customers made up 28%. In fact, a single commercial customer accounted for 12% of its 2019 revenue. Losing any one of those major customers could have a big financial impact on Palantir’s business.The argument relies on the idea that Palantir is incapable of maintaining the business relationship that it has forged in the private and public sectors.But that doesn’t hold up based on Palantir’syear-end 2020 report.Government customer revenue increased by 77% between 2019 and 2020 at Palantir. $234.3 million of that $264.7 million increase was attributable to existing customers. Therefore, 88% of the government revenue increase came from existing contracts. This is a company that is providing services that its clients respect and will pay more for over time, not one in danger of losing customers.On the commercial side Palantir saw its revenues grow 22% in the same time frame. $59.7 million (69.9%) of the $85.4 million in revenue growth was from existing clients. Again, satisfied customers is the narrative I see here.If Palantir is doing something wrong by expanding their business within the contracts they currently have, then what should they do? Would markets be more impressed if the company were to land clients only not to see their respective businesses grow on an account-by-account basis?Show me that Palantir’s business isn’t growing based on revenues, profits or some other meaningful basis and I’d be inclined to be bearish long term. That isn’t the case.VerdictBears are essentially arguing that Palantir keeps ingratiating themselves to those that they provide services for. However, Palantir simply continues to grow those businesses, and that’s somehow a bad thing?Seems an odd argument to me.I think PLTR stock prices now are an excellent spot from which to establish a position.","news_type":1},"isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":344500786,"gmtCreate":1618412847145,"gmtModify":1704710516913,"author":{"id":"3567123115497130","authorId":"3567123115497130","name":"JORDBULL","avatar":"https://static.tigerbbs.com/4b95853b965a467335a4ba3aa97aa3df","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567123115497130","idStr":"3567123115497130"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344500786","repostId":"1144756307","repostType":4,"repost":{"id":"1144756307","pubTimestamp":1618404805,"share":"https://ttm.financial/m/news/1144756307?lang=&edition=fundamental","pubTime":"2021-04-14 20:53","market":"us","language":"en","title":"Play Tilray Stock for the Aphria Stock Merger Arbitrage Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=1144756307","media":"InvestorPlace","summary":"This short-term opportunity will become a buy-and-hold investment once the merger closes.\n\nAphria(NA","content":"<blockquote>\n <b>This short-term opportunity will become a buy-and-hold investment once the merger closes.</b>\n</blockquote>\n<p><b>Aphria</b>(NASDAQ:<b><u>APHA</u></b>) stockholders will vote April 16 on themega-mergerwith itslongtime Canadian cannabis-market competitor,<b>Tilray</b>(NASDAQ:<b><u>TLRY</u></b>). Since the merger announcement, TLRY stock and APHA shares have gone in different directions due to the merger arbitrage opportunity.</p>\n<p>When the Aphria-Tilray merger was announced back in mid-December, both pot stocks exploded.</p>\n<p>In terms of revenue, the combination will create the biggest cannabis company in the world. So, the enthusiasm surrounding the merger makes sense.</p>\n<p>In the year thus far, Aphria stock is up 135.3%, and TLRY gained 139.2%. Under the terms of the deal, Aphria stockholders willreceive 62% of the combined entity.</p>\n<p>Some made money by buying Aphria and shorting Tilray. However, at this point, the more interesting discussion is whether the combined entity will have the legs to run in an ailing industry.</p>\n<p>It has been struggling due to the Canadian cannabis market going through an essential round of bubble bursting.</p>\n<p>On that end, I believe the merger ultimately creates an interesting stock that has a much better chance of competing in the Canadian cannabis sector while keeping an eye on the U.S. market.</p>\n<p><b>TLRY Stock Suffered With Cannabis Sector</b></p>\n<p>Let’s face it. Before this merger was announced, both Tilray and the wider cannabis segment were suffering. Gross margin, operating margin, net margin, return on assets, return on equity, and ROIC is all in the red for TLRY.</p>\n<p>According to Refinitiv data, the Canadian pharmaceutical and cannabis company has disappointed Wall Street analysts’ consensus earnings estimates10 times in the last 12 quarters. The company recently reported a negative EPS of 45 cents versus a consensus of negative 14.7, a miss of 206.1%.</p>\n<p>There are some bright spots, though. For the full year 2020,total revenue jumped 26% to $210.5 million, driven by international medical revenue and growth in its Canadian adult-use business.</p>\n<p>Out of the two companies, Aphria is clearly the better company on operating metrics. Sales rose 235.8% over the last five years at a compound annual growth rate (CAGR). Growth in the top line hasn’t translated to profitability as yet. But on every major operating metric, the company is doing better than Tilray.</p>\n<p><b>APHA Stock Maintains Upper Hand</b></p>\n<p>No surprises Aphria has the upper hand in this deal. Shareholders will get a total of 0.8381 shares of Tilray for each of their Aphria shares and control the combined entity.</p>\n<p>Aphria’s and Tilray’s share prices will diverge in the run-up to the merger due to the market arbitrage opportunity. Basically, a market arbitrage opportunity is when you simultaneously buy and sell securities to take advantage of a price difference.</p>\n<p>Usually, when a merger is announced, the target company’s share price rises. The opposite occurs in the case of the acquiring company. The acquiring company has to pay a premium to purchase the target company, often using debt to finance the acquisition.</p>\n<p><b>Combined Entity Will Be a Strong European Player</b></p>\n<p>After the merger, the surviving entity will become the biggest cannabis company globally in terms of revenue.</p>\n<p>Wider marijuana decriminalization in the U.S. is imminent.Democrats have unified controlof the White House, Senate, and House for the first time since 2010.</p>\n<p>At the moment, neither Aphria nor Tilray has a strong American presence. In contrast, the European medicinal cannabis market and the Canadian recreational market represent the company’s strongest market segments.</p>\n<p>That’s not to say it couldn’t make a splash in the U.S., though. With greater size and scale, it can make further inroads into the American market since that is the major lifeline for most cannabis aspirants at the moment.</p>\n<p>Although it’s fairly large, the Canadian market doesn’t hold a candle to the California weed industry, let alone the entire U.S.</p>\n<p>Hence, the foray into America is a given, and with the combination, the merged entity has a better chance of performing well in the market.</p>\n<p><b>Bottom Line on Tilray Stock</b></p>\n<p>For now, investors should keep taking advantage of the arbitrage opportunity. In the last three months alone, shares have increased by 90%. During the same time, Tilray stock is up 74.7%. The divergence will increase as we move closer to the merger.</p>\n<p>If you are bullish on the merger, you can hold onto APHA stock post the combination. But I would take my profits after the merger closes and wait for a couple of earnings reports before deciding to put your capital back into the company.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Play Tilray Stock for the Aphria Stock Merger Arbitrage Opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPlay Tilray Stock for the Aphria Stock Merger Arbitrage Opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 20:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/04/play-tilray-stock-for-the-aphria-stock-merger-arbitrage-opportunity/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This short-term opportunity will become a buy-and-hold investment once the merger closes.\n\nAphria(NASDAQ:APHA) stockholders will vote April 16 on themega-mergerwith itslongtime Canadian cannabis-...</p>\n\n<a href=\"https://investorplace.com/2021/04/play-tilray-stock-for-the-aphria-stock-merger-arbitrage-opportunity/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc.","APHA":"Aphria Inc."},"source_url":"https://investorplace.com/2021/04/play-tilray-stock-for-the-aphria-stock-merger-arbitrage-opportunity/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144756307","content_text":"This short-term opportunity will become a buy-and-hold investment once the merger closes.\n\nAphria(NASDAQ:APHA) stockholders will vote April 16 on themega-mergerwith itslongtime Canadian cannabis-market competitor,Tilray(NASDAQ:TLRY). Since the merger announcement, TLRY stock and APHA shares have gone in different directions due to the merger arbitrage opportunity.\nWhen the Aphria-Tilray merger was announced back in mid-December, both pot stocks exploded.\nIn terms of revenue, the combination will create the biggest cannabis company in the world. So, the enthusiasm surrounding the merger makes sense.\nIn the year thus far, Aphria stock is up 135.3%, and TLRY gained 139.2%. Under the terms of the deal, Aphria stockholders willreceive 62% of the combined entity.\nSome made money by buying Aphria and shorting Tilray. However, at this point, the more interesting discussion is whether the combined entity will have the legs to run in an ailing industry.\nIt has been struggling due to the Canadian cannabis market going through an essential round of bubble bursting.\nOn that end, I believe the merger ultimately creates an interesting stock that has a much better chance of competing in the Canadian cannabis sector while keeping an eye on the U.S. market.\nTLRY Stock Suffered With Cannabis Sector\nLet’s face it. Before this merger was announced, both Tilray and the wider cannabis segment were suffering. Gross margin, operating margin, net margin, return on assets, return on equity, and ROIC is all in the red for TLRY.\nAccording to Refinitiv data, the Canadian pharmaceutical and cannabis company has disappointed Wall Street analysts’ consensus earnings estimates10 times in the last 12 quarters. The company recently reported a negative EPS of 45 cents versus a consensus of negative 14.7, a miss of 206.1%.\nThere are some bright spots, though. For the full year 2020,total revenue jumped 26% to $210.5 million, driven by international medical revenue and growth in its Canadian adult-use business.\nOut of the two companies, Aphria is clearly the better company on operating metrics. Sales rose 235.8% over the last five years at a compound annual growth rate (CAGR). Growth in the top line hasn’t translated to profitability as yet. But on every major operating metric, the company is doing better than Tilray.\nAPHA Stock Maintains Upper Hand\nNo surprises Aphria has the upper hand in this deal. Shareholders will get a total of 0.8381 shares of Tilray for each of their Aphria shares and control the combined entity.\nAphria’s and Tilray’s share prices will diverge in the run-up to the merger due to the market arbitrage opportunity. Basically, a market arbitrage opportunity is when you simultaneously buy and sell securities to take advantage of a price difference.\nUsually, when a merger is announced, the target company’s share price rises. The opposite occurs in the case of the acquiring company. The acquiring company has to pay a premium to purchase the target company, often using debt to finance the acquisition.\nCombined Entity Will Be a Strong European Player\nAfter the merger, the surviving entity will become the biggest cannabis company globally in terms of revenue.\nWider marijuana decriminalization in the U.S. is imminent.Democrats have unified controlof the White House, Senate, and House for the first time since 2010.\nAt the moment, neither Aphria nor Tilray has a strong American presence. In contrast, the European medicinal cannabis market and the Canadian recreational market represent the company’s strongest market segments.\nThat’s not to say it couldn’t make a splash in the U.S., though. With greater size and scale, it can make further inroads into the American market since that is the major lifeline for most cannabis aspirants at the moment.\nAlthough it’s fairly large, the Canadian market doesn’t hold a candle to the California weed industry, let alone the entire U.S.\nHence, the foray into America is a given, and with the combination, the merged entity has a better chance of performing well in the market.\nBottom Line on Tilray Stock\nFor now, investors should keep taking advantage of the arbitrage opportunity. In the last three months alone, shares have increased by 90%. During the same time, Tilray stock is up 74.7%. The divergence will increase as we move closer to the merger.\nIf you are bullish on the merger, you can hold onto APHA stock post the combination. But I would take my profits after the merger closes and wait for a couple of earnings reports before deciding to put your capital back into the company.","news_type":1},"isVote":1,"tweetType":1,"viewCount":66,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}